前列腺酸性磷酸酶:前列腺癌的新型诊疗靶点
本文综述前列腺酸性磷酸酶(ACP3)作为前列腺癌诊疗靶点的生物学特征与临床转化进展。ACP3在超过95%的前列腺癌中表达,具有肿瘤表达高且一致、去势抵抗性疾病中持续表达、关键非癌组织表达极低等优势。DNA编码化合物库技术推动了高亲和力ACP3配体的开发,[68Ga]Ga-OncoACP3-DOTA PET首次人体分子成像已成功实施,早期数据显示诊断性能可与PSMA-PET竞争、唾液腺/泪腺和肾脏摄取明显降低。
要点
- ACP3在超过95%的前列腺癌中表达,可作为PSMA的补充或替代靶点。
- [68Ga]Ga-OncoACP3-DOTA PET早期临床显示诊断性能可与PSMA-PET竞争。
- ACP3靶向探针唾液腺/泪腺和肾脏摄取明显降低,药代动力学有利。
核心结论
- 现有证据将ACP3定位为有前景的下一代诊疗靶点,有望克服PSMA方法的关键局限并扩展前列腺癌精准治疗选择。
研究设计与样本
- 综述,总结ACP3的生物学特征、其作为生物标志物的历史与当前角色以及新兴治疗应用,重点聚焦ACP3靶向分子成像与放射性配体治疗。
主要发现
- ACP3在超过95%的前列腺癌中表达,具有肿瘤表达高且一致、去势抵抗性疾病中持续表达、关键非癌组织表达极低的特点。
- 利用DNA编码化合物库进行配体发现,已开发出高亲和力ACP3靶向化合物,并成功实现[68Ga]Ga-OncoACP3-DOTA PET首次人体分子成像。
- 早期临床数据显示诊断性能可与PSMA-PET竞争,唾液腺/泪腺和肾脏摄取明显降低,药代动力学有利,表现为肿瘤摄取随时间增加、肿瘤/本底比值随时间改善。
- 临床前与转化证据进一步支持ACP3靶向放射性配体治疗的可行性。
关键数值与推荐
- ACP3在超过95%的前列腺癌中表达。
- PSMA靶向诊疗存在临床相关局限,包括相当一部分肿瘤PSMA表达异质或缺失,以及唾液腺、泪腺和肾脏的剂量限制性脱靶摄取。
临床怎么用
- ACP3靶向分子成像可作为PSMA-PET的补充或替代选择,尤其适用于PSMA表达异质或缺失的肿瘤。
- ACP3靶向探针唾液腺/泪腺和肾脏摄取明显降低,可能减少剂量限制性脱靶效应。
- ACP3靶向放射性配体治疗的临床前与转化证据支持其可行性,但尚待进一步临床验证。
局限性
- 早期临床数据有限,ACP3靶向放射性配体治疗主要基于临床前与转化证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA)-targeted theranostics have transformed the diagnostic and therapeutic landscape of prostate cancer; however, clinically relevant limitations persist, including heterogeneous or absent PSMA expression in a substantial subset of tumors and dose-limiting off-target uptake in salivary glands, lacrimal glands and kidneys. Prostatic acid phosphatase (ACP3), expressed in more than 95% of prostate cancers, has re-emerged as a promising complementary and potentially alternative theranostic target. ACP3 demonstrates favorable biological characteristics, including high and consistent tumor expression, persistence in castration-resistant disease, and minimal expression in critical but non-cancerous tissues. Recent advances in ligand discovery using DNA-encoded chemical libraries have enabled the development of high-affinity ACP3-targeting compounds, with successful first-in-human molecular imaging with [68Ga]Ga-OncoACP3-DOTA PET. Early clinical data demonstrate competitive diagnostic performance compared with PSMA-PET, markedly reduced salivary/lacrimal gland and renal uptake, and advantageous pharmacokinetics characterized by increasing tumor uptake and improving tumor-to-background ratios over time. Preclinical and translational evidence further supports the feasibility of ACP3-targeted radioligand therapy. This review summarizes the biological features of ACP3, its historical and current role as a biomarker, and emerging therapeutic applications, with a primary focus on ACP3-targeted molecular imaging and radioligand therapy. The available evidence positions ACP3 as a compelling next-generation theranostic target with the potential to overcome key limitations of PSMA-based approaches and expand precision treatment options for patients with prostate cancer.
引用
- Seifert KE, Reimann J, Rust M, et al. The prostatic acid phosphatase in prostate cancer: A novel theranostic target. Semin Nucl Med. 2026. PMID: 41925410. doi:10.1053/j.semnuclmed.2026.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。